Nautilus: 3 Key Takeaways for Long-Term Investors
Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
Nautilus Biotechnology, Inc. Q3 2026 Earnings Call Summary
Nautilus (NAUT) Q3 2026 Earnings Call Transcript
Nautilus Biotechnology Q3 Earnings Call Highlights
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Nautilus Biotechnology (NASDAQ:NAUT) Q3 Earnings Beat and Pipeline Progress Drive Premarket Surge
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus Biotechnology Q3 2026 Earnings Call Transcript
Nautilus Biotechnology Announces Participation In SEEDS Research Consortium, Which Was Awarded Up To $51.7M By The Advanced Research Projects Agency For Health
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
Voyager Will Take Center Stage In Nautilus' Commercial Push
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Nautilus Biotechnology Files $300M Shelf Registration, Including $125M Nasdaq Common Stock ATM Offering Through TD Cowen
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback
Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...
Nautilus Biotechnology Q2 Earnings Call Highlights
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.